The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis (Q36454787)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis (English)

1 reference

Europe PubMed Central

14 August 2017

anti-retroviral agent

0 references

0 references

Rochelle P. Walensky

10

1 reference

Europe PubMed Central

14 August 2017

object named as

Jason R Andrews

1

0 references

object named as

Elena Losina

8

0 references

2

object named as

Stephen D Lawn

1 reference

Europe PubMed Central

14 August 2017

4

object named as

Robin Wood

1 reference

Europe PubMed Central

14 August 2017

Kenneth A. Freedberg

9

object named as

Kenneth A Freedberg

1 reference

Europe PubMed Central

14 August 2017

5

object named as

Farzad Noubary

1 reference

Europe PubMed Central

14 August 2017

author name string

Corina Rusu

3

1 reference

Europe PubMed Central

14 August 2017

Melissa A Bender

6

1 reference

Europe PubMed Central

14 August 2017

C Robert Horsburgh

7

1 reference

Europe PubMed Central

14 August 2017

language of work or name

0 references

publication date

1 May 2012

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

26

1 reference

Europe PubMed Central

14 August 2017

8

1 reference

Europe PubMed Central

14 August 2017

987-995

1 reference

Europe PubMed Central

14 August 2017

Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Rapid molecular detection of tuberculosis and rifampin resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

The risk and timing of tuberculosis diagnosed in smear-negative TB suspects: a 12 month cohort study in Harare, Zimbabwe

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures -- a meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Scaling up antiretroviral therapy in South Africa: the impact of speed on survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Financing and cost-effectiveness analysis of public-private partnerships: provision of tuberculosis treatment in South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

30 September 2017

Delayed diagnosis of tuberculosis in patients with human immunodeficiency virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

28 June 2018

Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

21 September 2018

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

21 September 2018

CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517815

4 December 2018

The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22333751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands

1 reference

https://pubmed.ncbi.nlm.nih.gov/22333751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/QAD.0B013E3283522D47

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36454787&oldid=1632244779"